Category : Seeking Alpha

InventHelp Inventor Develops Improved Vanity Mirror (CSK-807)

PITTSBURGH, Nov. 7, 2025 /PRNewswire/ -- "I wanted to create a newly designed vanity mirror that would offer advantages over existing mirrors," said an inventor, from Columbia, S.C., "so I invented the NEW TWIST VANITY MIRROR. My design enables you t...

AHN West Penn First in Country to Perform Hysterectomy with New Robotic-Assisted Surgery System as Part of Investigative Clinical Trial

PITTSBURGH, Nov. 7, 2025 /PRNewswire/ -- Allegheny Health Network (AHN) West Penn Hospital today announced it is the first U.S. site to participate in a clinical study involving use of the Medtronic Hugo™ robotic-assisted surgery (RAS) system in gyne...

Duke Energy shares ways to save energy and money as coldest air of the season arrives next week

Empowering customers with tools and tips to manage costs during well-below-average November temperatures CHARLOTTE, N.C., Nov. 7, 2025 /PRNewswire/ -- With the coldest air of the season forecast to arrive early next week, Duke Energy is committed to...

Piedmont Natural Gas offers programs and tips to help customers save on energy bills as colder temps hit the Southeast next week

Company's payment plans, assistance programs and energy-saving tips and tools can help customers manage seasonal bills B-roll: Energy efficiency tips for natural gas CHARLOTTE, N.C., Nov. 7, 2025 /PRNewswire/ -- With colder-than-normal temperatures a...

Round Table Pizza Brings Legendary Flavor to Austin Area

West Coast-Born Pizza Franchise Continues Expansion in Texas with Round Rock, TX Opening

ETC’s Commercial/Industrial Unit Awarded Contracts Totaling $9.1 Million

SOUTHAMPTON, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation’s (OTCID: ETCC) (“ETC” or the “Company”) Environmental Testing and Simulation Systems (“ETSS”) business unit announced it has been awarded a $7.0 million contra...

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the SITC 2025 Annual Meeting

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to reconstitute immunity to treat cancer and...

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of hu...

Legrand Acquires Avtron Power Solutions, a Global Provider of Load Banks & Power Quality Solutions

WEST HARTFORD, Conn., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Legrand®, a global leader in electrical and digital building infrastructures, announced that it has acquired Avtron Power Solutions, a leading global provider of load banks and power quality s...

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant brain tum...

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients –

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents

Precision Optics Announces Product Development Agreement to Deliver Next-Generation Augmented Reality Sub-Systems for Fighter Pilots

GARDNER, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt o...

Wrap and LETAC Lead Policy Development for Human Centered Non-Lethal Integration of Humanoid Robotics in Public Safety

Partnership built to scale growing policy market and public demand to address future-state concerns around humanoid and robotic systems, recognizing ethical and operational demands and risks to help ensure non-lethal innovation Partnership built to s...